Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

750 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A case of marked rectal stenosis due to Douglas' pouch metastasis of renal pelvic carcinoma successfully treated with salvage enfortumab vedotin: correlation between serum KL-6 levels and tumor response.
Akatsuka J, Kimura G, Katsu A, Hasegawa H, Mikami H, Yanagi M, Endo Y, Takeda H, Toyama Y, Kondo Y. Akatsuka J, et al. Among authors: kimura g. IJU Case Rep. 2023 Sep 26;6(6):449-453. doi: 10.1002/iju5.12645. eCollection 2023 Nov. IJU Case Rep. 2023. PMID: 37928289 Free PMC article.
Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study.
Tamada S, Nozawa M, Ohba K, Mizuno R, Takamoto A, Ohe C, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Kimura G, Tomita Y, Nonomura N, Eto M. Tamada S, et al. Among authors: kimura g. Int J Clin Oncol. 2023 Feb;28(2):289-298. doi: 10.1007/s10147-022-02256-z. Epub 2022 Dec 19. Int J Clin Oncol. 2023. PMID: 36534263 Free PMC article.
Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart review.
Yonese J, Hinata N, Masui S, Nakai Y, Shirotake S, Takeuchi A, Inamoto T, Nozawa M, Ueda K, Etsunaga T, Osawa T, Uemura M, Kimura G, Numakura K, Yamana K, Miyake H, Fukasawa S, Morishima N, Ito H, Uemura H. Yonese J, et al. Among authors: kimura g. Int J Urol. 2023 Sep;30(9):762-771. doi: 10.1111/iju.15206. Epub 2023 May 29. Int J Urol. 2023. PMID: 37248753
Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.
Tomita Y, Kobayashi K, Kimura G, Oya M, Uemura H, Nishiyama H, Galsky MD, Nasroulah F, Collette S, Broughton E, Ünsal-Kaçmaz K, Kamisuki Y, Bajorin DF. Tomita Y, et al. Among authors: kimura g. Jpn J Clin Oncol. 2023 Jan 6;53(1):16-25. doi: 10.1093/jjco/hyac155. Jpn J Clin Oncol. 2023. PMID: 36300304 Free PMC article. Clinical Trial.
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Symeonides S, Hajek J, Ferguson T, Chang YH, Lee JL, Haas N, Sawrycki P, Sarwar N, Gross-Goupil M, Thiery-Vuillemin A, Mahave M, Kimura G, Perini RF, Saretsky TL, Bhattacharya R, Xu L, Powles T. Choueiri TK, et al. Among authors: kimura g. Oncologist. 2024 Feb 2;29(2):142-150. doi: 10.1093/oncolo/oyad231. Oncologist. 2024. PMID: 37589219 Free PMC article. Clinical Trial.
Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care).
Osawa T, Fujii Y, Kimura G, Kitamura H, Nagashima Y, Iizumi S, Osaka T, Tsubouchi R, Shinohara N. Osawa T, et al. Among authors: kimura g. BMJ Open. 2023 Jul 26;13(7):e070275. doi: 10.1136/bmjopen-2022-070275. BMJ Open. 2023. PMID: 37495393 Free PMC article.
750 results